Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Cervantes, F."" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 30
Tytuł:
Momelotinib reduces transfusion requirements in patients with myelofibrosis.
Autorzy:
Mesa R; Mays Cancer Center, UT Health San Antonio Cancer Center, San Antonio, TX, USA.
Oh ST; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Gerds AT; Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Gupta V; Department of Medicine, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Catalano J; Haematology Department, Monash University & Frankston Hospital, Frankston, Australia.
Cervantes F; Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Devos T; Department of Hematology, University Hospitals Leuven and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium.
Hus M; Hematooncology Department, Medical University of Lublin, Lublin, Poland.
Kiladjian JJ; Université de Paris, AP-HP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM, Paris, France.
Lech-Maranda E; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
McLornan D; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Palmer J; Division of Hematology and Medical Oncology, Mayo Clinic Hospital, Phoenix, AZ, USA.
Platzbecker U; Department of Hematology, Cellular Therapy and Hemostaseology, Leipzig University Hospital, Leipzig, Germany.
Treliński J; Department of Hematology, Medical University of Lodz, Lodz, Poland.
Shimoda K; Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
Donahue R; Biometrics, Sierra Oncology Inc, San Mateo, CA, USA.
D'Hollander K; Biostatistics, International Drug Development Institute, Louvain-la-Neuve, Belgium.
Kowalski M; Research and Early Development, Sierra Oncology Inc, San Mateo, CA, USA.
Verstovsek S; Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Jul; Vol. 63 (7), pp. 1718-1722. Date of Electronic Publication: 2022 Mar 07.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Primary Myelofibrosis*/drug therapy
Benzamides ; Humans ; Pyrimidines/therapeutic use
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
Autorzy:
Mora B; Hematology, Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Rumi E; Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Università di Pavia, Pavia, Italy.
Guglielmelli P; CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Department of Experimental and Clinical Medicine, Azienda ospedaliera-Universitaria Careggi, University of Florence, Florence, Italy.
Barraco D; Hematology, Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Maffioli M; Hematology, Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Rambaldi A; Hematology and BMT Unit, ASST Papa Giovanni XXIII, University of Milan, Bergamo, Italy.
Caramella M; Ospedale Niguarda Cà Granda, Milano, Italy.
Komrokji R; Moffit Cancer Center, Tampa, Florida.
Gotlib J; Stanford University, Palo Alto, California.
Kiladjian JJ; Hôpital Saint-Louis et Université Paris Diderot, Paris, France.
Cervantes F; Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Devos T; Department of Hematology, University Hospitals Leuven and Laboratory of Experimental Transplantation, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
Palandri F; Policlinico S. Orsola-Malpighi, Bologna, Italy.
De Stefano V; Università Cattolica del Sacro Cuore, Roma, Italy.
Ruggeri M; Ospedale S. Bortolo, Vicenza, Italy.
Silver RT; Weill Cornell Medical College, New York.
Benevolo G; Centro Oncologico Ematologico Subalpino (COES), Torino, Italy.
Albano F; Università di Bari, Bari, Italy.
Cavalloni C; Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Università di Pavia, Pavia, Italy.
Pietra D; Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Università di Pavia, Pavia, Italy.
Barbui T; FROM Research Foundation, ASST Papa Giovanni XXIII, Bergamo, Italy.
Rotunno G; CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Department of Experimental and Clinical Medicine, Azienda ospedaliera-Universitaria Careggi, University of Florence, Florence, Italy.
Cazzola M; Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Università di Pavia, Pavia, Italy.
Vannucchi AM; CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Department of Experimental and Clinical Medicine, Azienda ospedaliera-Universitaria Careggi, University of Florence, Florence, Italy.
Giorgino T; Biophysics Institute, National Research Council of Italy, Milan, Italy.; Department of Biosciences, University of Milan, Milan, Italy.
Passamonti F; Hematology, Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2019 Aug; Vol. 8 (9), pp. 4089-4092. Date of Electronic Publication: 2019 Jun 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasms, Second Primary/*epidemiology
Polycythemia Vera/*epidemiology
Primary Myelofibrosis/*epidemiology
Skin Neoplasms/*epidemiology
Thrombocythemia, Essential/*epidemiology
Cohort Studies ; Female ; Humans ; Incidence ; Janus Kinase Inhibitors/therapeutic use ; Male ; Neoplasms, Second Primary/drug therapy ; Polycythemia Vera/drug therapy ; Primary Myelofibrosis/drug therapy ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
Autorzy:
Verstovsek S; The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine, 1515 Holcombe Blvd, Unit 418, Houston, TX, 77030, USA. .
Gotlib J; Stanford Cancer Institute, Stanford, CA, USA.
Mesa RA; UT Health San Antonio Cancer Center - An NCI Designated Cancer Center, San Antonio, TX, USA.
Vannucchi AM; Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, and Laboratorio Congiunto, University of Florence, Florence, Italy.
Kiladjian JJ; Centre d'Investigations Cliniques (INSERM CIC 1427), Hôpital Saint-Louis and Université Paris Diderot, Paris, France.
Cervantes F; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Harrison CN; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Paquette R; Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sun W; Incyte Corporation, Wilmington, DE, USA.
Naim A; Incyte Corporation, Wilmington, DE, USA.
Langmuir P; Incyte Corporation, Wilmington, DE, USA.
Dong T; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Gopalakrishna P; Novartis Pharma AG, Basel, Switzerland.
Gupta V; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2017 Sep 29; Vol. 10 (1), pp. 156. Date of Electronic Publication: 2017 Sep 29.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Anemia/*chemically induced
Primary Myelofibrosis/*drug therapy
Pyrazoles/*therapeutic use
Disease Progression ; Double-Blind Method ; Female ; Humans ; Male ; Nitriles ; Primary Myelofibrosis/mortality ; Primary Myelofibrosis/pathology ; Pyrazoles/adverse effects ; Pyrazoles/pharmacology ; Pyrimidines ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.
Autorzy:
Hernández-Boluda JC; Hematology Department, Hospital Clínico Universitario, INCLIVA, Valencia, Spain.
Correa JG; Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
García-Delgado R; Hematology Department, Hospital Virgen de la Victoria, Málaga, Spain.
Martínez-López J; Hematology Department, Hospital 12 de Octubre, Madrid, Spain.
Alvarez-Larrán A; Hematology Department, Hospital del Mar, Barcelona, Spain.
Fox ML; Hematology Department, Hospital Vall d'Hebron, Barcelona, Spain.
García-Gutiérrez V; Hematology Department, Hospital Ramón y Cajal, Madrid, Spain.
Pérez-Encinas M; Hematology Department, Hospital Clínico, Santiago de Compostela, Spain.
Ferrer-Marín F; Hematology and Medical Oncology Department, Hospital Morales Meseguer, IMIB-Arrixaca, UCAM, Murcia, Spain.
Mata-Vázquez MI; Hematology Department, Hospital Costa del Sol, Marbella, Spain.
Raya JM; Hematology Department, Hospital Universitario de Canarias, Tenerife, Spain.
Estrada N; Hematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Badalona, Spain.
García S; Hematology Department, Hospital La Fe, IIS La Fe, Valencia, Spain.
Kerguelen A; Hematology Department, Hospital La Paz, Madrid, Spain.
Durán MA; Hematology Department, Hospital Son Espases, Mallorca, Spain.
Albors M; Hematology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain.
Cervantes F; Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2017 Apr; Vol. 98 (4), pp. 407-414. Date of Electronic Publication: 2017 Jan 19.
Typ publikacji:
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms:
Anemia*/blood
Anemia*/drug therapy
Anemia*/mortality
Primary Myelofibrosis*/blood
Primary Myelofibrosis*/drug therapy
Primary Myelofibrosis*/mortality
Hematinics/*administration & dosage
Aged ; Disease-Free Survival ; Erythropoietin/blood ; Female ; Ferritins/blood ; Hematinics/adverse effects ; Humans ; Leukocyte Count ; Male ; Middle Aged ; Sex Factors ; Spain/epidemiology ; Survival Rate ; Thrombosis/blood ; Thrombosis/chemically induced ; Thrombosis/mortality
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Long-term results of prednisone treatment for the anemia of myelofibrosis.
Autorzy:
Hernández-Boluda JC; a Hematology and Medical Oncology Department, Hospital Clínico Universitario , Valencia , Spain.
Martínez-Trillos A; b Hematology Department, Hospital Clínic , IDIBAPS, University of Barcelona , Barcelona , Spain.
García-Gutiérrez V; c Hematology Department, Hospital Ramón y Cajal , Madrid , Spain.
Ferrer-Marín F; d Hospital Morales Meseguer , Murcia , Spain.
Xicoy B; e Hematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol , Badalona , Spain.
Alvarez-Larrán A; f Hematology Department, Hospital del Mar-IMIM , Barcelona , Spain.
Kerguelen A; g Hematology Department, Hospital La Paz , Madrid , Spain.
Barba P; h Hematology Department, Hospital Vall d'Hebron , Barcelona , Spain.
Gómez M; a Hematology and Medical Oncology Department, Hospital Clínico Universitario , Valencia , Spain.
Herrera JC; a Hematology and Medical Oncology Department, Hospital Clínico Universitario , Valencia , Spain.
Correa JG; b Hematology Department, Hospital Clínic , IDIBAPS, University of Barcelona , Barcelona , Spain.
Cervantes F; b Hematology Department, Hospital Clínic , IDIBAPS, University of Barcelona , Barcelona , Spain.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2016; Vol. 57 (1), pp. 120-4. Date of Electronic Publication: 2015 Jun 18.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Anemia/*drug therapy
Anemia/*etiology
Anti-Inflammatory Agents/*therapeutic use
Immunosuppressive Agents/*therapeutic use
Prednisone/*therapeutic use
Primary Myelofibrosis/*complications
Aged ; Anemia/diagnosis ; Anti-Inflammatory Agents/administration & dosage ; Anti-Inflammatory Agents/adverse effects ; Bone Marrow/pathology ; Erythrocyte Indices ; Female ; Humans ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/adverse effects ; Male ; Middle Aged ; Mutation ; Prednisone/administration & dosage ; Prednisone/adverse effects ; Primary Myelofibrosis/diagnosis ; Primary Myelofibrosis/genetics ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.
Autorzy:
Kröger NM; Department of Stem Cell Transplantation, University Hospital, Hamburg, Germany.
Deeg JH; Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA, USA.
Olavarria E; Department of Hematology, Hospital of Navarra, Navarra Health Service, Pamplona, Spain.
Niederwieser D; Department of Haematology, Clinical Oncology and Hemostasiology, University of Leipzig, Leipzig, Germany.
Bacigalupo A; Ospedale San Martino, Genoa, Italy.
Barbui T; Research Foundation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Rambaldi A; Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Mesa R; Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA.
Tefferi A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Griesshammer M; Academic Department of Hematology and Oncology, Johannes Wesling Teaching Hospital, Hans-Nolte-Strasse 1, Minden, Germany.
Gupta V; Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Harrison C; Department of Haematology Guy's and St Thomas' NHS Foundation Trust, London, UK.
Alchalby H; Department of Stem Cell Transplantation, University Hospital, Hamburg, Germany.
Vannucchi AM; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Cervantes F; Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Robin M; Department of Hematology and Bone Marrow Transplantation, Saint Louis Hospital, Paris, France.
Ditschkowski M; Department of Bone Marrow Transplantation, WTZ, Comprehensive Cancer Centre, University Hospital Essen, Essen, Germany.
Fauble V; Mayo Clinic Cancer Center, Scottsdale, AZ, USA.
McLornan D; Department of Haematology Guy's and St Thomas' NHS Foundation Trust, London, UK.; Department of Haematological Medicine, King's College Hospital, London, UK.
Ballen K; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
Popat UR; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Passamonti F; Division of Hematology, Department of Medicine, University Hospital Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
Rondelli D; University of Illinois Hospital & Health Sciences System and University of Illinois Cancer Center, Chicago, IL, USA.
Barosi G; Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2126-33. Date of Electronic Publication: 2015 Aug 21.
Typ publikacji:
Journal Article; Review; Systematic Review
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Primary Myelofibrosis/*therapy
Donor Selection ; Histocompatibility Testing ; Humans ; Primary Myelofibrosis/mortality ; Transplantation Conditioning ; Transplantation, Homologous
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
Autorzy:
Finazzi MC; Hematology division, A.O. Papa Giovanni XXIII, Bergamo, Italy.
Carobbio A; Research Foundation, A.O. Papa Giovanni XXIII, Bergamo, Italy.
Cervantes F; Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Isola IM; Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Vannucchi AM; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Guglielmelli P; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Rambaldi A; Hematology division, A.O. Papa Giovanni XXIII, Bergamo, Italy.
Finazzi G; Hematology division, A.O. Papa Giovanni XXIII, Bergamo, Italy.
Barosi G; Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Barbui T; 1] Hematology division, A.O. Papa Giovanni XXIII, Bergamo, Italy [2] Research Foundation, A.O. Papa Giovanni XXIII, Bergamo, Italy.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 May; Vol. 29 (5), pp. 1209-10. Date of Electronic Publication: 2014 Dec 08.
Typ publikacji:
Letter; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Mutation*
Calreticulin/*genetics
Primary Myelofibrosis/*genetics
Receptors, Thrombopoietin/*genetics
DNA Mutational Analysis ; Europe ; Follow-Up Studies ; Humans ; Incidence ; Janus Kinase 2/genetics ; Primary Myelofibrosis/complications ; Primary Myelofibrosis/diagnosis ; Risk Factors ; Thrombocythemia, Essential/genetics ; Thrombosis/complications ; Thrombosis/genetics ; Treatment Outcome
Raport
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Novel therapies for myelofibrosis.
Autorzy:
Stein BL; a Northwestern University Feinberg School of Medicine , Chicago , IL , USA.; b Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago , IL , USA.
Cervantes F; c Hospital Clínic, Hematology Department, Institut d'Investigació Biomédica August Pi i Sunyer , University of Barcelona , Barcelona , Spain.
Giles F; b Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago , IL , USA.
Harrison CN; d Department of Haematology , Guy's and St. Thomas' National Health Service Foundation Trust , London , UK.
Verstovsek S; e Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2015; Vol. 56 (10), pp. 2768-78. Date of Electronic Publication: 2015 May 18.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Molecular Targeted Therapy*
Primary Myelofibrosis/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Animals ; Drug Resistance/genetics ; Gene Expression Regulation/drug effects ; Humans ; Janus Kinases/antagonists & inhibitors ; Janus Kinases/genetics ; Janus Kinases/metabolism ; Mutation ; Nuclear Proteins/genetics ; Nuclear Proteins/metabolism ; Primary Myelofibrosis/genetics ; Primary Myelofibrosis/metabolism ; Promyelocytic Leukemia Protein ; Protein Kinase Inhibitors/pharmacology ; STAT Transcription Factors/antagonists & inhibitors ; STAT Transcription Factors/genetics ; STAT Transcription Factors/metabolism ; Signal Transduction/drug effects ; Transcription Factors/genetics ; Transcription Factors/metabolism ; Tumor Suppressor Proteins/genetics ; Tumor Suppressor Proteins/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
Autorzy:
Guglielmelli P; Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Lasho TL; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Rotunno G; Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Score J; Wessex Reg Genetics Lab, Salisbury, UK.
Mannarelli C; Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Pancrazzi A; Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Biamonte F; Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Pardanani A; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Zoi K; Haematology Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece.
Reiter A; III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany.
Duncombe A; Department of Haematology, Southampton University Hospital, Southampton, UK.
Fanelli T; Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Pietra D; Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Rumi E; Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
Finke C; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Gangat N; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Ketterling RP; Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
Knudson RA; Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
Hanson CA; Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
Bosi A; Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Pereira A; Hemotherapy & Hemostasis, Hospital Clínic, Barcelona, Spain.
Manfredini R; Centre for Regenerative Medicine 'Stefano Ferrari', University of Modena and Reggio Emilia, Modena, Italy.
Cervantes F; Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Barosi G; Center for the Study of Myelofibrosis, IRCCS Policlinico S.Matteo Foundation, Pavia, Italy.
Cazzola M; Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation & University of Pavia, Pavia, Italy.
Cross NC; Faculty of Medicine, University of Southampton, Southampton, UK.
Vannucchi AM; Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Tefferi A; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2014 Sep; Vol. 28 (9), pp. 1804-10. Date of Electronic Publication: 2014 Feb 19.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Mutation*
Primary Myelofibrosis/*genetics
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Calreticulin/genetics ; Female ; Humans ; Male ; Middle Aged ; Primary Myelofibrosis/mortality ; Prognosis ; Repressor Proteins/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Leukemia risk models in primary myelofibrosis: an International Working Group study.
Autorzy:
Tefferi A
Pardanani A
Gangat N
Begna KH
Hanson CA
Van Dyke DL
Caramazza D
Vannucchi AM
Morra E
Cazzola M
Pereira A
Cervantes F
Passamonti F
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2012 Jun; Vol. 26 (6), pp. 1439-41. Date of Electronic Publication: 2012 Jan 13.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Models, Statistical*
Leukemia/*etiology
Leukemia/*mortality
Primary Myelofibrosis/*complications
Primary Myelofibrosis/*mortality
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Female ; Follow-Up Studies ; Humans ; International Agencies ; Karyotyping ; Leukemia/therapy ; Male ; Middle Aged ; Primary Myelofibrosis/therapy ; ROC Curve ; Risk Factors ; Survival Rate ; Young Adult
Raport
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
Autorzy:
Pardanani A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Vannucchi AM
Passamonti F
Cervantes F
Barbui T
Tefferi A
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2011 Feb; Vol. 25 (2), pp. 218-25. Date of Electronic Publication: 2010 Nov 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Janus Kinases/*antagonists & inhibitors
Primary Myelofibrosis/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Humans ; Myeloproliferative Disorders/drug therapy ; Nitriles ; Pyrazoles/therapeutic use ; Pyrimidines ; Pyrrolidines/therapeutic use ; Sulfonamides/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
Autorzy:
Barosi G
Mesa RA
Thiele J
Cervantes F
Campbell PJ
Verstovsek S
Dupriez B
Levine RL
Passamonti F
Gotlib J
Reilly JT
Vannucchi AM
Hanson CA
Solberg LA
Orazi A
Tefferi A
Pokaż więcej
Corporate Authors:
International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)
Źródło:
Leukemia [Leukemia] 2008 Feb; Vol. 22 (2), pp. 437-8. Date of Electronic Publication: 2007 Aug 30.
Typ publikacji:
Letter
MeSH Terms:
Polycythemia Vera*/complications
Polycythemia Vera*/diagnosis
Primary Myelofibrosis*/diagnosis
Primary Myelofibrosis*/etiology
Thrombocythemia, Essential*/complications
Thrombocythemia, Essential*/diagnosis
Humans ; Practice Guidelines as Topic
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients.
Autorzy:
Alvarez-Larrán A; Department of Hematology, Hospital del Mar, Barcelona, Spain.
Cervantes F
Bellosillo B
Giralt M
Juliá A
Hernández-Boluda JC
Bosch A
Hernández-Nieto L
Clapés V
Burgaleta C
Salvador C
Arellano-Rodrigo E
Colomer D
Besses C
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2007 Jun; Vol. 21 (6), pp. 1218-23. Date of Electronic Publication: 2007 Apr 12.
Typ publikacji:
Journal Article
MeSH Terms:
Primary Myelofibrosis/*etiology
Thrombocythemia, Essential/*complications
Vascular Diseases/*etiology
Adolescent ; Adult ; Child ; Child, Preschool ; Humans ; Incidence ; Janus Kinase 2/genetics ; Mutation ; Risk Factors ; Stroke/etiology ; Survival Analysis ; Thrombocythemia, Essential/epidemiology ; Thrombocythemia, Essential/mortality ; Thrombosis/etiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution.
Autorzy:
Cervantes F; Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain. />Alvarez-Larrán A
Arellano-Rodrigo E
Granell M
Domingo A
Montserrat E
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2006 Jan; Vol. 20 (1), pp. 55-60.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Primary Myelofibrosis/*epidemiology
Thrombosis/*epidemiology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cardiovascular Diseases/epidemiology ; Comorbidity ; Female ; Follow-Up Studies ; Humans ; Incidence ; Male ; Middle Aged ; Multivariate Analysis ; Primary Myelofibrosis/diagnosis ; Primary Myelofibrosis/therapy ; Prognosis ; Risk ; Risk Factors ; Spain/epidemiology ; Survival Rate ; Thrombosis/diagnosis ; Thrombosis/therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Idiopathic myelofibrosis associated with classic polyarteritis nodosa.
Autorzy:
Camós M; Institute of Hematology and Oncology, Department of Hematology, Postgraduate School of Hematology Farreras-Valentí, Hospital Clinic, Villarroel 170, University of Barcelona, Barcelona, 08036 Spain.
Arellano-Rodrigo E
Abelló D
Muntañola A
Ferrer A
Grau JM
Cervantes F
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2003 Mar; Vol. 44 (3), pp. 539-41.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Autoimmune Diseases/*complications
Polyarteritis Nodosa/*complications
Primary Myelofibrosis/*complications
Abdominal Pain/etiology ; Autoimmune Diseases/diagnosis ; Autoimmune Diseases/drug therapy ; Autoimmune Diseases/immunology ; Cyclophosphamide/adverse effects ; Cyclophosphamide/therapeutic use ; Diagnostic Errors ; Fatal Outcome ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Middle Aged ; Polyarteritis Nodosa/diagnosis ; Polyarteritis Nodosa/drug therapy ; Polyarteritis Nodosa/immunology ; Prednisone/therapeutic use ; Primary Myelofibrosis/immunology ; Raynaud Disease/etiology ; Scleroderma, Systemic/diagnosis ; Splenic Infarction/etiology ; Splenomegaly/etiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Idiopathic myelofibrosis associated with ulcerative colitis.
Autorzy:
Arellano-Rodrigo E; Institute of Hematology and Oncology, Department of Hematology, Postgraduate School of Hematology Farreras-Valentí, Barcelona, Spain.
Esteve J
Giné E
Panés J
Cervantes F
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2002 Jul; Vol. 43 (7), pp. 1481-3.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Colitis, Ulcerative/*complications
Primary Myelofibrosis/*etiology
Aged ; Autoimmunity ; Colitis, Ulcerative/diagnosis ; Colitis, Ulcerative/immunology ; Humans ; Male ; Primary Myelofibrosis/diagnosis ; Primary Myelofibrosis/immunology ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Idiopathic myelofibrosis associated with primary biliary cirrhosis.
Autorzy:
Hernández-Boluda JC; Department of Hematology, Institute of Hematology and Oncology, Postgraduate School of Hematology Farreras-Valentí, IDIBAPS, Hospital Clínic, University of Barcelona, Villarroel, Spain.
Jiménez M
Rosiñol L
Cervantes F
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2002 Mar; Vol. 43 (3), pp. 673-4.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Liver Cirrhosis, Biliary/*complications
Primary Myelofibrosis/*etiology
Aged ; Autoimmune Diseases/complications ; Fatal Outcome ; Female ; Humans ; Primary Myelofibrosis/diagnosis ; Primary Myelofibrosis/immunology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival.
Autorzy:
Cervantes F; Institute of Hematology and Oncology, Hematology Department, Postgraduate School of Hematology 'Farrreras Valentí', Hospital Clínic, IDIBAPS, University of Barcelona, Spain. />Barosi G
Hernández-Boluda JC
Marchetti M
Montserrat E
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2001 May; Vol. 66 (5), pp. 324-7.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Primary Myelofibrosis/*complications
Adolescent ; Adult ; Bone Marrow Transplantation ; Budd-Chiari Syndrome/complications ; Budd-Chiari Syndrome/diagnosis ; Female ; Humans ; Leukocyte Count ; Leukocytosis/complications ; Male ; Primary Myelofibrosis/diagnosis ; Primary Myelofibrosis/mortality ; Prognosis ; Splenomegaly ; Survival Rate ; Thrombocytosis/complications
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 30

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies